Scinovex
article Open AccessTop 10% cited

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

BMC Cancer · 2015 · Vol. 15(1) · pp. 767–767
J. Joshua SmithOliver S. ChowMarc J. GollubGarrett M. NashLarissa K. TempleMartin R. WeiserJosé G. GuillemPhilip B. PatyKarin AvilaJulio García‐Aguilar

Abstract

NCT02008656.

Colorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasColorectal Cancer Screening and DetectionMedicineTotal mesorectal excisionColorectal cancerFOLFOXNeoadjuvant therapyRectumChemotherapyOncologyOxaliplatinSurgery

MeSH terms

CapecitabineOxaliplatinAdenocarcinomaAdultAntineoplastic Combined Chemotherapy ProtocolsLeucovorinFemaleFluorouracilHumansMaleOrganoplatinum CompoundsProspective StudiesQuality of LifeRectal NeoplasmsDisease-Free Survival

Funding

  • U.S. Department of Health and Human Services
  • University of Chicago
  • Cleveland Clinic
  • University of Washington
  • University of Rochester
  • University of South Florida
  • MedStar Health Research Institute
  • National Institutes of Health
  • University of California, San Francisco
  • University of California, Irvine
  • Medical Center, University of Rochester
  • National Cancer Institute
Citations
381
FWCI
9.05
field-weighted impact
References
21
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management · Scinovex